Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study.

Agarwala, Sanjiv S; Kirkwood, John M; Gore, Martin; Dreno, Brigitte; Thatcher, Nicholas; Czarnetski, Beate; Atkins, Michael; Buzaid, Antonio; Skarlos, Dimosthenis; Rankin, Elaine M

Agarwala, Sanjiv S; Kirkwood, John M; Gore, Martin; Dreno, Brigitte; Thatcher, Nicholas; Czarnetski, Beate; Atkins, Michael; Buzaid, Antonio; Skarlos, Dimosthenis; Rankin, Elaine M.

Affiliation

Agarwala SS; Division of Hematology Oncology, University of Pittsburgh Medical Center Pavilion, 5150 Centre Ave, Pittsburgh, PA 15232, USA. agarwalass@msx.upmc.edu

J Clin Oncol ; 22(11): 2101-7, 2004 Jun 01.

Article in En | MEDLINE | ID: mdl-15169796

Subject(s)

Antineoplastic Agents, Alkylating/therapeutic use; Brain Neoplasms/drug therapy; Brain Neoplasms/secondary; Dacarbazine/analogs & derivatives; Dacarbazine/therapeutic use; Melanoma/drug therapy; Melanoma/secondary; Skin Neoplasms/pathology; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating/adverse effects; Brain Neoplasms/mortality; Dacarbazine/adverse effects; Disease-Free Survival; Female; Humans; Male; Melanoma/mortality; Middle Aged; Survival Rate; Temozolomide; United States/epidemiology

Search on Google

XML

PubMed Links

Database: MEDLINE Main subject: Skin Neoplasms / Brain Neoplasms / Antineoplastic Agents, Alkylating / Dacarbazine / Melanoma Type of study: Clinical_trials / Risk_factors_studies Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Country/Region as subject: America do norte Language: En Year: 2004 Type: Article

Search on Google

XML

PubMed Links